Helogen Raises $7.1M for Orbital Biomanufacturing
Helogen raised $7.1M to develop orbital biology and biomaterial manufacturing infrastructure.
Space manufacturing is trying to move from experiments into repeatable production infrastructure.
What happened
Helogen raised a $7.1M seed round to develop its HEL-IOS platform for orbital biology and biomaterial manufacturing. The company is preparing missions to test hardware, production records and medical-material use cases in microgravity.
The round supports a crossover category between SpaceTech, biotech and advanced manufacturing.
Why it matters
Microgravity can create unusual conditions for biology and materials, but the hard part is turning that into a reliable service. Regulated products need quality control, repeatable processes and documentation, not just interesting science.
Helogen’s signal is about infrastructure: building the systems that could make orbital manufacturing less like one-off research and more like a usable platform.
The bigger picture
SpaceTech is broadening beyond launch and satellites. As access to orbit becomes more regular, startups are exploring what can be made, tested or improved in space. The category is early, but it could create new infrastructure markets if the economics and regulation work.